Compass Therapeutics is a Boston biopharmaceutical company developing antibody drugs to treat cancer. CMPX reports earnings on Wed, Nov 4, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 6 firms (5 buy, 1 hold, 0 sell).
Prices, price targets and earnings estimates for CMPX are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in CMPX in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CMPX is in one of them and how their past CMPX trades turned out.
Compass Therapeutics is a biopharmaceutical company based in Boston, Massachusetts, that develops antibody drugs for cancer. Its lead candidate, tovecimig, is designed to block two signaling pathways that tumors use to grow new blood vessels, and it is being tested in patients with biliary tract cancer. The company also has three other clinical stage candidates that target immune system pathways, including CD137 and PD-1. None of these candidates has been approved for sale.
